comprehensive -WSS

comprehensive

author：focus 2025-09-30 21:04:24 - browse：3774

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

knowledge

WSS

BMI, flaws aside, is found to be useful estimate of body fat in youth

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Health AI adoption puts security, privacy startups on investors' radar

App could help diagnose ear infections more accurately — and at home

Let's speed up science by embracing open access publishing

Ultragenyx gene therapy for rare liver ailment succeeds in late

knowledge

comprehensive

focus

Cancer drug shortages should be causing more outrage

With trial win, GSK could get blood cancer drug back on market

New air purifier tech could be key to improving indoor air quality

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Peter Hotez and the public health issue of online harassment

App could help diagnose ear infections more accurately — and at home

Duchenne breakthrough therapy leaves behind pioneering families

Plastic surgeons increase patient psychiatric screenings

Virginia high school admissions case could be legal follow

SCOTUS questions limit to govt efforts to fight misinformation

hotspot

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Virtual Event: March of the Biosimilars

Nurses recount patients attacks

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

FDA's Pazdur wants cancer trials to range beyond China alone

Wikipedia

focus

knowledge

Wikipedia